Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring.

OBJECTIVE To compare the glycemic profiles of patients with type 1 diabetes treated with either an implantable insulin pump or pancreas or islet transplantation by the means of the continuous glucose monitoring system (CGMS; Minimed, Sylmar, CA). RESEARCH DESIGN AND METHODS The CGMS enabled recording of subcutaneous glucose concentrations (range 2.2-22 mmol/l) over 72 h (288 measurements per day). Over 3 days, 26 patients with type 1 diabetes were connected to a CGMS: 10 patients were treated with intraperitoneal insulin infusion through an implantable pump (IPII), 9 patients were treated with simultaneous pancreas-kidney transplantation (SPK), and 7 patients were treated with pancreatic islet transplantation after kidney grafting (IAK). All SPK patients and four IAK patients were insulin independent, whereas three IAK patients had partial graft function and reduced exogenous insulin needs. Glucose control was evaluated by the mean glucose concentration, glucose variability, and the number and duration of hypoglycemic events (<3.3 mmol/l) over 3 days. RESULTS The mean glucose concentration and the glucose variability in SPK and IAK patients were significantly lower than those observed in patients treated with IPII: 5.38 +/- 1.12 and 5.83 +/- 0.81 vs. 7.81 +/- 1.55 mmol/l (P < 0.001) and 1.40 +/- 0.42 and 1.32 +/- 0.53 vs. 3.47 +/- 1.66 mmol/l (P < 0.001), respectively. Furthermore, the mean glucose concentration and the glucose variability were comparable between SPK and IAK patients. Over 3 days, no hypoglycemic events were observed in SPK patients and insulin-independent IAK patients. A total of 4.12 +/- 1.66 hypoglycemic events were detected in the IPII patient group, whereas only 0.66 +/- 0.57 events were observed in IAK patients with partial graft function (P < 0.001). The duration of the hypoglycemic events was significantly longer in IPII patients as compared with IAK patients: 64 +/- 33 vs. 30 +/- 15 min for the day period and 130 +/- 62 vs. 30 +/- 27 min for the night period (P < 0.001). CONCLUSIONS Use of subcutaneous CGMS confirms that islet transplantation can be as efficient as pancreas transplantation in restoring good metabolic control and reducing blood glucose variability. Metabolic improvement due to use of an implantable insulin pump requires insulin delivery by a closed loop.

[1]  J. Perlman.  Resuscitation--air versus 100% oxygen. , 2002, Pediatrics.

[2]  H. Hanaire-Broutin,et al.  Intérêt du CGMS (Continuous Glucose Monitoring System) dans l'exploration du diabète de type 1 de l'adulte , 2001 .

[3]  F. Ris,et al.  Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999–2000) , 2001, Diabetologia.

[4]  J F Elliott,et al.  Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. , 2001, Diabetes.

[5]  V. Karsten,et al.  Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. , 2001, Diabetes care.

[6]  A. Secchi,et al.  Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. , 2001, Diabetes.

[7]  H. Chase,et al.  Continuous subcutaneous glucose monitoring in children with type 1 diabetes. , 2001, Pediatrics.

[8]  B. Dunkin,et al.  Simultaneous Cadaver Pancreas Living-Donor Kidney Transplantation: A New Approach for the Type 1 Diabetic Uremic Patient , 2000, Annals of surgery.

[9]  J. Selam.  [How to measure glycemic instability?]. , 2000, Diabetes & metabolism.

[10]  P. Morel,et al.  Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations. , 2000, Transplantation.

[11]  R. Kandaswamy,et al.  Decreased surgical risks of pancreas transplantation in the modern era. , 2000, Annals of surgery.

[12]  J. Mastrototaro,et al.  Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. , 1999, Diabetes research and clinical practice.

[13]  J. Selam,et al.  Implantable insulin pumps , 1999, The Lancet.

[14]  J. Ringers,et al.  Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure , 1999, The Lancet.

[15]  J. Bolinder,et al.  Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. , 1999, Transplantation.

[16]  R. Robertson,et al.  Hypoglycemia after pancreas transplantation. , 1998, Diabetes care.

[17]  N. Jeandidier,et al.  Long Term Safety and Efficacy of Intraperitoneal Insulin Infusion by Means of Implantable Pumps , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  K. Boudjema,et al.  Possible involvement of Von Willebrand factor in pancreatic graft thrombosis after kidney-pancreas transplantation: a retrospective study. , 1998, Clinical transplantation.

[19]  R. Bonnecaze,et al.  Measurement and modeling of the transient difference between blood and subcutaneous glucose concentrations in the rat after injection of insulin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  U. Ungerstedt,et al.  Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison With Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue During Ordinary Life Conditions , 1997, Diabetes Care.

[21]  J. Gautier,et al.  Are the implications of the Diabetes Control and Complications Trial (DCCT) feasible in daily clinical practice? , 1996, Diabetes & metabolism.

[22]  A. Secchi,et al.  Islet transplantation in IDDM patients , 1996, Diabetologia.

[23]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[24]  W. F. Taylor,et al.  Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.

[25]  A. Zung,et al.  Continuous subcutaneous glucose monitoring in children with type 1 diabetes. , 2002, Pediatrics.

[26]  V. Melki,et al.  [Indication of CGMS (Continuous Glucose Monitoring System) in the functionnal investigations of adult type 1 diabetic patients]. , 2001, Diabetes & metabolism.

[27]  J. Mastrototaro,et al.  The MiniMed continuous glucose monitoring system. , 2000, Diabetes technology & therapeutics.

[28]  J. Mastrototaro,et al.  The MiniMed Continuous Glucose Monitoring System (CGMS). , 1999, Journal of pediatric endocrinology & metabolism : JPEM.

[29]  G. Steil,et al.  Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. , 1999, The American journal of physiology.